Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Wang J, Liu Y, Li Z, Wang Z, Tan LX, Ryu MJ, Meline B, Du J, Young KH, Ranheim E, Chang Q, Zhang J.

Blood. 2011 Jul 14;118(2):368-79. doi: 10.1182/blood-2010-12-326058. Epub 2011 May 17.

PMID:
21586752
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K.

Blood. 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16.

PMID:
21163920
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.

Wang J, Liu Y, Tan LX, Lo JC, Du J, Ryu MJ, Ranheim EA, Zhang J.

Cell Cycle. 2011 Sep 1;10(17):2836-9. Epub 2011 Sep 1.

PMID:
21857161
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

Wang J, Kong G, Liu Y, Du J, Chang YI, Tey SR, Zhang X, Ranheim EA, Saba-El-Leil MK, Meloche S, Damnernsawad A, Zhang J, Zhang J.

Blood. 2013 Jun 27;121(26):5203-7. doi: 10.1182/blood-2012-12-475863. Epub 2013 May 17.

PMID:
23687087
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.

Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR, Fleming MD, Young KH, Pitot H, Zhang J.

Blood. 2010 Dec 23;116(26):5991-6002. doi: 10.1182/blood-2010-04-281527. Epub 2010 Oct 4.

PMID:
20921338
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.

Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K.

Cancer Discov. 2013 Sep;3(9):993-1001. doi: 10.1158/2159-8290.CD-13-0096. Epub 2013 Jun 3.

PMID:
23733505
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Oncogenic Kras initiates leukemia in hematopoietic stem cells.

Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS.

PLoS Biol. 2009 Mar 17;7(3):e59. doi: 10.1371/journal.pbio.1000059.

PMID:
19296721
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.

Wolf S, Rudolph C, Morgan M, Büsche G, Salguero G, Stripecke R, Schlegelberger B, Baum C, Modlich U.

Oncogene. 2013 Jun 20;32(25):3028-38. doi: 10.1038/onc.2012.329. Epub 2012 Jul 30.

PMID:
22847614
[PubMed - indexed for MEDLINE]
9.

Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.

Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, Shannon K, Morrison SJ.

Nature. 2013 Dec 5;504(7478):143-7. doi: 10.1038/nature12830. Epub 2013 Nov 27.

PMID:
24284627
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.

Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA, Wang J, Zhang J.

J Biol Chem. 2013 Jun 21;288(25):18219-27. doi: 10.1074/jbc.M113.475376. Epub 2013 May 14. Erratum in: J Biol Chem. 2013 Dec 27;288(52):37368.

PMID:
23673656
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.

Parikh C, Subrahmanyam R, Ren R.

Blood. 2006 Oct 1;108(7):2349-57. Epub 2006 Jun 8.

PMID:
16763213
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T.

Cancer Cell. 2004 Apr;5(4):375-87.

PMID:
15093544
[PubMed - indexed for MEDLINE]
Free Article
13.

Palmitoylation of oncogenic NRAS is essential for leukemogenesis.

Cuiffo B, Ren R.

Blood. 2010 Apr 29;115(17):3598-605. doi: 10.1182/blood-2009-03-213876. Epub 2010 Mar 3.

PMID:
20200357
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.

Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF, Fleming MD.

Blood. 2009 Feb 5;113(6):1304-14. doi: 10.1182/blood-2008-01-134262. Epub 2008 Dec 9.

PMID:
19066392
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Kindler T, Cornejo MG, Scholl C, Liu J, Leeman DS, Haydu JE, Fröhling S, Lee BH, Gilliland DG.

Blood. 2008 Oct 15;112(8):3373-82. doi: 10.1182/blood-2008-03-147587. Epub 2008 Jul 28.

PMID:
18663146
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.

Doisaki S, Muramatsu H, Shimada A, Takahashi Y, Mori-Ezaki M, Sato M, Kawaguchi H, Kinoshita A, Sotomatsu M, Hayashi Y, Furukawa-Hibi Y, Yamada K, Hoshino H, Kiyoi H, Yoshida N, Sakaguchi H, Narita A, Wang X, Ismael O, Xu Y, Nishio N, Tanaka M, Hama A, Koike K, Kojima S.

Blood. 2012 Aug 16;120(7):1485-8. doi: 10.1182/blood-2012-02-406090. Epub 2012 Jul 2.

PMID:
22753870
[PubMed - indexed for MEDLINE]
Free Article
17.

Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.

Xu J, Hedberg C, Dekker FJ, Li Q, Haigis KM, Hwang E, Waldmann H, Shannon K.

Blood. 2012 Jan 26;119(4):1032-5. doi: 10.1182/blood-2011-06-358960. Epub 2011 Dec 5.

PMID:
22144181
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele.

Wang Z, Feng Y, Bardeesy N, Wong KK, Liu XY, Ji H.

PLoS One. 2012;7(5):e37308. doi: 10.1371/journal.pone.0037308. Epub 2012 May 11. Erratum in: PLoS One. 2012;7(7). doi:10.1371/annotation/0671c124-a263-49e9-9c23-421fd125db2c. Bardessy, Nabeel [corrected to Bardeesy, Nabeel].

PMID:
22606359
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, Mulloy JC, Zhang J.

J Clin Invest. 2014 Jun 2;124(6):2762-73. doi: 10.1172/JCI74182. Epub 2014 May 8.

PMID:
24812670
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG.

J Clin Invest. 2004 Feb;113(4):528-38.

PMID:
14966562
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk